hts

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

Membrane proteins are a class of proteins widely found in biological cell membranes, playing essential roles in the structure and function of cells. Based on their location and function, membrane proteins can be classified into three main categories: peripheral membrane proteins, integral membrane proteins, and lipid-anchored proteins. Membrane proteins encompass a variety of functional proteins, including glycoproteins, carrier proteins, and enzymes. They are often linked to carbohydrate molecules, which can transmit signals into the cell by undergoing structural changes, participating in signal transduction processes. Membrane proteins perform a range of critical functions, including substance transport, signal transduction, cell recognition, and energy conversion. In drug development, membrane proteins, especially G protein-coupled receptors (GPCRs), ion channels, and transporters, are of particular interest. Many diseases are related to the malfunction of specific membrane proteins. Therefore, drugs designed to target these proteins can regulate their activity, aiming to treat diseases. TargetMol has collected 6422 compounds that target membrane proteins, which can be used for membrane protein-related scientific research and drug screening, suitable for high-throughput and high-content screening.

TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development, signaling pathway research, drug repurposing and other research.

A unique collection of 5084 compounds for high-throughput screening and high-content screening,

A unique collection of 4981 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A unique collection of 3170 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3500 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1500 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 10240 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2760 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3660 drugs with anti-cancer activity or potential anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1180 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS;

A unique collection of 1470 compounds with defined autophagy-inducing or -inhibitory activity for research in autophagy, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 3064 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 19730 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 2073 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3177 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1440 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening;

Diversity: Selected from 1,600,000 drug-like compounds, 10000compounds representing 5000 scaffolds selected from a large drug-like chemical source;

A unique collection of 750 CNS-Penetrant compounds for high throughput screening (HTS) and high content screening (HCS);